

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-8 (cancelled)

9. (currently amended) A composition comprising an immunogenic peptide of less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, wherein the peptide comprises the p53 sequence of SMPPPGTRV (SEQ ID NO:4).

Claims 10-15 (cancelled)

16. (previously presented) The composition of claim 9, further comprising a pharmaceutically acceptable carrier.

Claims 17-24 (cancelled)

25. (new) A composition comprising

i) an immunogenic peptide of less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, wherein the peptide comprises the p53 sequence of SMPPPGTRV (SEQ ID NO:4); and

ii) one or more moieties selected from the group consisting of:

(a) a T helper peptide;

(b) a lipid; and

(c) a different peptide that induces a cytotoxic T lymphocyte response,
wherein said immunogenic peptide is linked to said one or more moieties.

26. (new) The composition of claim 25, further comprising a pharmaceutically acceptable carrier.

27. (new) The composition of claim 25, further comprising a liposome.

28. (new) The composition of claim 25, wherein said one or more moieties is a T helper peptide.

29. (new) The composition of claim 25, wherein said one or more moieties is a lipid.

30. (new) The composition of claim 25, wherein said one or more moieties is a different peptide that induces a cytotoxic T lymphocyte response.

31. (new) The composition of claim 9, further comprising a liposome.

32. (new) The composition of claim 9, further comprising an antigen presenting cell (APC).

33. (new) The composition of claim 25, further comprising an antigen presenting cell (APC).

34. (new) The composition of claim 9, further comprising a dendritic cell.

35. (new) The composition of claim 25, further comprising a dendritic cell.